[ad_1] A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial…
Tag: Respiratory syncytial virus
GSK sues Pfizer claiming RSV vaccine patent infringement
[ad_1] Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims New York-based…
FDA approves GSK’s RSV vaccine for older adults, world’s first shot against virus
[ad_1] A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages…
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
[ad_1] We recognize you are attempting to access this website from a country belonging to the European Economic Area (EEA) including the EU which enforces the General Data Protection Regulation…
Moderna, Pfizer’s new race: The RSV vaccine FDA approval process
[ad_1] The Covid vaccine is here to stay after a development process that broke the record books at both Moderna and Pfizer, but a new golden age ofvaccines may only…